Lynn Durham is the founder of Stalicla. Stalicla has raised $30M in total funding. Latest round: Seed. Backed by SPRIM Global Investments Pte, Ltd.
Lynn Durham is the Founder & CEO of Stalicla, a Swiss clinical-stage biopharmaceutical company. She has raised seed funding to build a machine-learning platform for autism spectrum disorder (ASD), aiming to identify drug treatments by grouping autistic individuals based on biological signatures. Durham is currently advancing IND applications towards the FDA and planning Phase 2 trials in the U.S. and Europe.
Full founder directory · Investor directory · Company funding database · Fundraising library